Justice Brett Kavanaugh, writing on behalf of the Supreme Court, wrote that while the plaintiffs did not have standing to sue over the FDA’s regulation of mifepristone, “it is not clear that no one else would have standing to challenge the FDA’s relaxed regulation of mifepristone.”
